Multiple Reaction Monitoring-Based Targeted Assays for the Validation of Protein Biomarkers in Brain Tumors

• DOI: 10.3389/fonc.2021.548243
• Publication Date: 2021-05-14T14:37:45Z
• Authors: Saicharan Ghantasala; Medha Gayathri J....; Deeptarup Biswas; Nikita Gahoi; Shuvolina Mukherjee; Manubhai KP; Mehar Un Nissa; Alisha Srivastava; Sridhar Epari; Prakash Shetty; Aliasgar Moiyadi; Sanjeeva Srivastava
• Keywords: Proteomics; FOS: Computer and information sciences; targeted proteomics; multiple reaction monitoring; S100 Proteins: Structure, Function, and Pathology; Protein Identification; Proteome; Bioinformatics; Tandem mass spectrometry; Omics; Apoptosis; Cancer research; Biochemistry; Gene; Mass Spectrometry; Computational biology; 03 medical and health sciences; Tandem Mass Spectrometry; Biochemistry, Genetics and Molecular Biology; Health Sciences; Quantitative proteomics; Molecular Biology; Biology; RC254-282; Spectroscopy; Chromatography; 0303 health sciences; Role of Clusterin in Cancer and Disease; Mass spectrometry; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Life Sciences; Glioma; Mass Spectrometry Techniques with Proteins; 3. Good health; gliomas; Chemistry; Clusterin; Oncology; Calcium Modulated Proteins; Physical Sciences; Selected reaction monitoring; Medicine; Meningioma; Medulloblastoma

The emergence of omics technologies over the last decade has helped in advancement research and our understanding complex diseases like brain cancers. However, barring genomics, no other technology been able to find utility clinical settings. recent advancements mass spectrometry instrumentation have resulted proteomics becoming more sensitive reliable. Targeted proteomics, a relatively new branch spectrometry-based shown immense potential addressing shortcomings standard molecular biology-based techniques Western blotting Immunohistochemistry. In this study we demonstrate Multiple reaction monitoring (MRM), targeted approach, quantifying peptides from proteins Apolipoprotein A1 (APOA1), E (APOE), Prostaglandin H2 D-Isomerase (PTGDS), Vitronectin (VTN) Complement C3 (C3) cerebrospinal fluid (CSF) collected Glioma Meningioma patients. Additionally, also report transitions for - Vimentin (VIM), Cystatin-C (CST3) Clusterin (CLU) surgically resected tissues; Annexin (ANXA1), Superoxide dismutase (SOD2) VIM Microtubule associated protein-2 (MAP-2), Splicing factor 3B subunit 2 (SF3B2) Medulloblastoma tissues. To knowledge, is first reporting use MRM validate three types malignancies two different bio-specimens. Future studies involving large cohort samples aimed at accurately detecting with roles could potentially result panel showing ability classify grade tumors. Successful application these ultimately offer alternative strategies increased accuracy, sensitivity lower turnaround time making them translatable clinics.